.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Daiichi Sankyo
Teva
Dow
Merck
Chubb
Cerilliant
Colorcon
UBS

Generated: December 12, 2017

DrugPatentWatch Database Preview

EMEND Drug Profile

« Back to Dashboard

When do Emend patents expire, and when can generic versions of Emend launch?

Emend is a drug marketed by Merck, Msd Merck Co, and Merck And Co Inc. and is included in three NDAs. There are three patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and twenty-four patent family members in forty-eight countries and seven supplementary protection certificates in four countries.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Merck And Co IncEMENDfosaprepitant dimegluminePOWDER;INTRAVENOUS022023-002Nov 12, 2010APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Msd Merck CoEMENDaprepitantFOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Msd Merck CoEMENDaprepitantFOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Merck And Co IncEMENDfosaprepitant dimegluminePOWDER;INTRAVENOUS022023-001Jan 25, 2008DISCNYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Msd Merck CoEMENDaprepitantFOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co IncEMENDfosaprepitant dimegluminePOWDER;INTRAVENOUS022023-002Nov 12, 2010► Subscribe► Subscribe
Merck And Co IncEMENDfosaprepitant dimegluminePOWDER;INTRAVENOUS022023-001Jan 25, 2008► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-001Mar 26, 2003► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003► Subscribe► Subscribe
Merck And Co IncEMENDfosaprepitant dimegluminePOWDER;INTRAVENOUS022023-001Jan 25, 2008► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-002Mar 26, 2003► Subscribe► Subscribe
MerckEMENDaprepitantCAPSULE;ORAL021549-003Jun 30, 2006► Subscribe► Subscribe
Merck And Co IncEMENDfosaprepitant dimegluminePOWDER;INTRAVENOUS022023-001Jan 25, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for EMEND

Drugname Dosage Strength RLD Submissiondate
aprepitantfor Oral Suspension125 mg/KitEmend11/23/2016
fosaprepitant dimeglumineInjection115 mg/vialEmend1/25/2012
fosaprepitant dimeglumineInjection150 mg/vialEmend1/25/2012
aprepitantCapsule40 mg, 80 mg and 125 mgEmend11/3/2008

Non-Orange Book Patents for Tradename: EMEND

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists► Subscribe
6,583,142 Polymorphic form of a tachykinin receptor antagonist► Subscribe
6,229,010 Polymorphic form of a tachykinin receptor antagonist► Subscribe
6,432,953 Polymorphic form of a tachykinin receptor antagonist► Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists► Subscribe
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EMEND

Country Document Number Estimated Expiration
Serbia50404► Subscribe
New Zealand501589► Subscribe
Colombia5590887► Subscribe
Poland211243► Subscribe
Spain2307820► Subscribe
MexicoPA04005563► Subscribe
Taiwan200301125► Subscribe
Bulgaria62811► Subscribe
Saudi Arabia1164► Subscribe
Czech Republic295410► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EMEND

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/021United Kingdom► SubscribePRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C/GB04/011United Kingdom► SubscribePRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
2004002,C0734381Lithuania► SubscribePRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
2004002Lithuania► SubscribePRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
2004Austria► SubscribePRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
C0010France► SubscribePRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
C0019France► SubscribePRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
UBS
Federal Trade Commission
Julphar
Citi
Covington
US Department of Justice
Novartis
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot